Weis Markets Reports Q4 Revenue of $1.29B
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 12 2026
0mins
Should l Buy WMK?
Reports Q4 revenue $1.29B vs. $1.23B last year. "Despite ongoing cautious customer spending, our Company achieved strong year-over-year sales growth, supported by significant price investments and record capital expenditures that enabled five new store openings and seven major remodels. We also delivered a 21% increase in e-commerce sales while benefitting from elevated pharmacy volume following a competitor's market exit," said Weis Markets, Inc. Chairman, President, and CEO Jonathan H. Weis. "In 2025, long-term investing remained a priority as we continued to support our future growth. Our store, supply chain and support associates helped us improve efficiencies and incorporate technologies that promote a superior customer experience. We are proud of our associates and grateful for their many contributions."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WMK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WMK
About WMK
Weis Markets, Inc. is a food retailer in Pennsylvania and surrounding states. The Company’s retail food stores sell groceries, dairy products, frozen foods, meats, seafood, fresh produce, floral, pharmacy services, deli products, prepared foods, bakery products, beer and wine, fuel and general merchandise items, such as health and beauty care and household products. The store's product selection includes national, local and private brands, including natural, gluten-free and organic varieties. It advertises its products and promotes its brand through digital and printed circulars; television ads; radio ads; e-mail blasts; and online via its Website, social media and mobile applications. It offers a Loyalty program that includes reward points that is redeemed for discounts on items in store, at the Company’s fuel stations or at one of its third-party fuel station partners. It owns and operates approximately 198 retail food stores, many of which have online ordered customer service.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investment Choices in Uncertain Markets
- Stable Dividend Returns: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting value investors in uncertain markets due to its consistent cash flow.
- Competitive Market Advantage: Ingles Markets operates hundreds of supermarkets in the Southeast and owns its own dairy processing facility; despite facing activist shareholder challenges, its vertical integration may unlock value for the company.
- Strategic Acquisition Plan: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance its competitive edge in the healthcare market.
- Market Volatility Response: In the current uncertain market, Weis, Ingles, and Prestige exemplify durability, cash flow, and relevance during economic downturns, prompting investors to cautiously observe and gradually build positions.
See More
Steady Investments in Uncertain Markets
- Stable Dividend Yield: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting investors seeking safe investments in uncertain market conditions.
- Value Investment Opportunity: Weis shares trade at a P/E ratio of about 15.6, below the consumer retail industry average of 19.2, and the recent drop below the 200-day moving average signals potential buying interest from value-oriented investors.
- Acquisition Driving Growth: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance the company's international presence in the health care market, likely boosting future revenue.
- Shareholder Activism Catalyst: Ingles Markets is facing a challenge from investment firm Summer Road LLC, which could act as a catalyst for unlocking value, although investors should proceed cautiously and consider gradual accumulation to mitigate potential risks.
See More
Weis Markets Faces Legal Investigation Over Financial Restatements
- Financial Restatement Announcement: Weis Markets disclosed on February 26, 2026, via an 8-K filing that its audited financial statements for fiscal years 2022 to 2024 will be restated due to inaccurately recorded inventory, which could impact the company's financial transparency and investor confidence.
- Stock Price Decline Impact: Following the announcement, Weis Markets' shares fell by $5.12, or approximately 7.16%, from $71.51 on February 25, 2026, indicating heightened market concerns over the company's financial health and potentially prompting investor sell-offs.
- Legal Rights Investigation: The law firm Bragar Eagel & Squire is investigating whether Weis Markets violated federal securities laws, and if negative findings arise, the company may face lawsuits and liability, further affecting its market performance.
- Investor Contact Information: The firm encourages affected Weis Markets shareholders to reach out for more information, highlighting the potential risks the company faces in legal matters, which could impact future financing and shareholder relations.
See More
Weis Markets Under Investigation, Stock Price Plummets
- Financial Restatement Announcement: On February 26, 2026, Weis Markets disclosed to the SEC that financial statements for fiscal years 2022 through 2024 will be restated due to inaccurately recorded and overstated inventory, which will impact the company's financial transparency and investor confidence.
- Stock Price Plunge: Following the restatement announcement, Weis Markets' stock price fell by $5.12, a decline of 7.16%, closing at $66.39, reflecting market concerns over the company's financial health and investor panic.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Weis Markets and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to legal liabilities and further damage its market reputation.
- Annual Report Delay: Weis Markets announced a delay in filing its 2025 Annual Report until the financial review and restatement process is completed, which may affect investor expectations and confidence regarding the company's future performance.
See More
Weis Markets Under Investigation, Stock Price Plummets
- Financial Restatement Announcement: On February 26, 2026, Weis Markets disclosed to the SEC that its financial statements for fiscal years 2022 to 2024 would be restated due to inaccurately recorded and overstated inventory, raising significant investor concerns.
- Stock Price Volatility: Following the announcement of the financial restatement, Weis Markets' stock price fell by $5.12, a decline of 7.16%, closing at $66.39, indicating market apprehension regarding the company's financial transparency.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Weis Markets and its executives have engaged in securities fraud or other unlawful business practices, advising investors to contact the firm for more information, highlighting potential legal risks that could impact the company's future operations.
- Annual Report Filing Delay: The company announced a delay in filing its 2025 Annual Report until the review and restatement process is completed, which may further undermine investor confidence and exert additional pressure on the company's stock price.
See More
Weis Markets Under Investigation, Stock Price Plummets
- Financial Restatement Announcement: On February 26, 2026, Weis Markets disclosed to the SEC that its audited financial statements for fiscal years 2022 to 2024 and interim statements for 2025 will be restated due to inaccurately recorded and overstated inventory, raising significant investor concerns.
- Stock Price Reaction: Following the announcement, Weis Markets' stock price fell by $5.12, a decline of 7.16%, closing at $66.39 per share, reflecting market apprehension regarding the company's financial transparency and potential legal risks.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Weis Markets and its executives engaged in securities fraud or other unlawful business practices, with investors advised to contact the firm to join the class action, potentially exposing the company to greater legal liabilities.
- Annual Report Delay: Weis Markets announced a delay in filing its 2025 Annual Report until the review and restatement process is completed, which may undermine investor confidence in the company's future financial health.
See More
Investment Choices in Uncertain Markets
- Stable Dividend Returns: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting value investors in uncertain markets due to its consistent cash flow.
- Competitive Market Advantage: Ingles Markets operates hundreds of supermarkets in the Southeast and owns its own dairy processing facility; despite facing activist shareholder challenges, its vertical integration may unlock value for the company.
- Strategic Acquisition Plan: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance its competitive edge in the healthcare market.
- Market Volatility Response: In the current uncertain market, Weis, Ingles, and Prestige exemplify durability, cash flow, and relevance during economic downturns, prompting investors to cautiously observe and gradually build positions.
See More
Steady Investments in Uncertain Markets
- Stable Dividend Yield: Weis Markets declared a quarterly dividend of $0.34 per share in February 2026, yielding approximately 2% annually, attracting investors seeking safe investments in uncertain market conditions.
- Value Investment Opportunity: Weis shares trade at a P/E ratio of about 15.6, below the consumer retail industry average of 19.2, and the recent drop below the 200-day moving average signals potential buying interest from value-oriented investors.
- Acquisition Driving Growth: Prestige Consumer Healthcare signed a definitive agreement to acquire the Breathe Right brand for $1.045 billion, expected to become its largest brand and enhance the company's international presence in the health care market, likely boosting future revenue.
- Shareholder Activism Catalyst: Ingles Markets is facing a challenge from investment firm Summer Road LLC, which could act as a catalyst for unlocking value, although investors should proceed cautiously and consider gradual accumulation to mitigate potential risks.
See More
Weis Markets Faces Legal Investigation Over Financial Restatements
- Financial Restatement Announcement: Weis Markets disclosed on February 26, 2026, via an 8-K filing that its audited financial statements for fiscal years 2022 to 2024 will be restated due to inaccurately recorded inventory, which could impact the company's financial transparency and investor confidence.
- Stock Price Decline Impact: Following the announcement, Weis Markets' shares fell by $5.12, or approximately 7.16%, from $71.51 on February 25, 2026, indicating heightened market concerns over the company's financial health and potentially prompting investor sell-offs.
- Legal Rights Investigation: The law firm Bragar Eagel & Squire is investigating whether Weis Markets violated federal securities laws, and if negative findings arise, the company may face lawsuits and liability, further affecting its market performance.
- Investor Contact Information: The firm encourages affected Weis Markets shareholders to reach out for more information, highlighting the potential risks the company faces in legal matters, which could impact future financing and shareholder relations.
See More
Weis Markets Under Investigation, Stock Price Plummets
- Financial Restatement Announcement: On February 26, 2026, Weis Markets disclosed to the SEC that financial statements for fiscal years 2022 through 2024 will be restated due to inaccurately recorded and overstated inventory, which will impact the company's financial transparency and investor confidence.
- Stock Price Plunge: Following the restatement announcement, Weis Markets' stock price fell by $5.12, a decline of 7.16%, closing at $66.39, reflecting market concerns over the company's financial health and investor panic.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Weis Markets and its executives engaged in securities fraud or other unlawful business practices, which could expose the company to legal liabilities and further damage its market reputation.
- Annual Report Delay: Weis Markets announced a delay in filing its 2025 Annual Report until the financial review and restatement process is completed, which may affect investor expectations and confidence regarding the company's future performance.
See More
Weis Markets Under Investigation, Stock Price Plummets
- Financial Restatement Announcement: On February 26, 2026, Weis Markets disclosed to the SEC that its financial statements for fiscal years 2022 to 2024 would be restated due to inaccurately recorded and overstated inventory, raising significant investor concerns.
- Stock Price Volatility: Following the announcement of the financial restatement, Weis Markets' stock price fell by $5.12, a decline of 7.16%, closing at $66.39, indicating market apprehension regarding the company's financial transparency.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Weis Markets and its executives have engaged in securities fraud or other unlawful business practices, advising investors to contact the firm for more information, highlighting potential legal risks that could impact the company's future operations.
- Annual Report Filing Delay: The company announced a delay in filing its 2025 Annual Report until the review and restatement process is completed, which may further undermine investor confidence and exert additional pressure on the company's stock price.
See More
Weis Markets Under Investigation, Stock Price Plummets
- Financial Restatement Announcement: On February 26, 2026, Weis Markets disclosed to the SEC that its audited financial statements for fiscal years 2022 to 2024 and interim statements for 2025 will be restated due to inaccurately recorded and overstated inventory, raising significant investor concerns.
- Stock Price Reaction: Following the announcement, Weis Markets' stock price fell by $5.12, a decline of 7.16%, closing at $66.39 per share, reflecting market apprehension regarding the company's financial transparency and potential legal risks.
- Legal Investigation Initiated: Pomerantz LLP is investigating whether Weis Markets and its executives engaged in securities fraud or other unlawful business practices, with investors advised to contact the firm to join the class action, potentially exposing the company to greater legal liabilities.
- Annual Report Delay: Weis Markets announced a delay in filing its 2025 Annual Report until the review and restatement process is completed, which may undermine investor confidence in the company's future financial health.
See More
